Navigation Links
Celladon Corporation Announces Publication of Advanced Heart Failure Clinical Trial Results With MYDICAR® Enzyme Replacement Therapy in the Journal Circulation
Date:6/27/2011

s the leading cause of hospitalization in Americans 65 years of age and older.

Additionally, the 12-month CUPID data show that heart failure, which is a progressive disease, became stabilized in high dose MYDICAR-treated patients: heart failure symptoms, exercise tolerance, serum biomarkers and cardiac function essentially improved or remained the same while these parameters deteriorated substantially in patients treated with placebo and concurrent optimal drug and device therapy.

The safety profile from this study was very favorable, with no significant side-effects from MYDICAR therapy.

Roger Hajjar, M.D., Director, Cardiovascular Research Center, Mount Sinai School of Medicine, NY, and co-founder of Celladon said: "While conventional treatment modalities have reduced heart failure mortality in the last 20 years, there remains a critical need for new therapeutic approaches in patients with advanced heart failure. The successful and safe completion of the phase 2 CUPID trial may give patients with heart failure a new therapeutic option in the future."

The CUPID Trial

The CUPID trial (Calcium Up-regulation by Percutaneous administration of gene therapy In cardiac Disease) is a randomized, double-blind, placebo-controlled study to assess the efficacy and safety of MYDICAR, a genetically targeted enzyme replacement therapy for advanced heart failure. Enrolled patients had severe forms of the disease defined by New York Heart Association Class III or IV heart failure, significantly impaired pumping function of their hearts (ejection fraction less than or equal to 35 percent), and less than half the normal ability to transport and utilize oxygen during exercise testing (VO2max less than or equal to 20 mL/kg/min). The CUPID trial ClinicalTrials.gov Identifier is NCT00454818.

Primary outcome measures included safety, worsening of heart failure leading to hospitalization, fr
'/>"/>

SOURCE Celladon Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo
2. The Journal of Cardiac Failure Publishes Results From Celladon Corporations First-in-Human Phase 1/2 Clinical Trial in Advanced Heart Failure
3. ShangPharma Corporation Named a Top Ten Chinese Outsourcing Enterprise
4. Fox Chase Cancer Center Signs Agreement with Life Technologies Corporation
5. China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011
6. China Cord Blood Corporation to Report Fourth Quarter and Full Year Fiscal 2011 Financial Results
7. Biomerix Corporation Reaches European Distribution Agreement with Cellon S.A.
8. Designed by Kids, Built by Volunteers: Roche, New Jersey Community Development Corporation, and KaBOOM! Build New Playground in Just One Day for Paterson Public School Children
9. Geminus Corporation Named Recipient of Second Annual Netsmart Technologies Customer Innovation Award
10. Terumo Americas Holding, Inc., Agrees to Acquire Harvest Technologies Corporation, a Leader in the Development of Point-of-Care Cellular Therapy
11. DURECT Corporation Announces First Quarter 2011 Financial Results and Update of Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... Aug. 26, 2015  The Diabetes Research Institute ... of Miami Miller School of Medicine, announced today ... to test for the first time a novel ... This FDA approved Phase I/II study builds upon ... is an important first step toward the development ...
(Date:8/26/2015)... Aug. 26, 2015 Intrexon Corporation (NYSE: ... the closing of its previously announced public offering of ... underwriters of their option to purchase an additional 731,707 ... of $41.00 per share.  The exercise of the underwriters, ... stock sold by Intrexon to 5,609,756 shares and increased ...
(Date:8/26/2015)... -- China Cord Blood Corporation (NYSE: CO ) ... of cord blood collection, laboratory testing, hematopoietic stem cell ... the Company has been informed that Magnum Opus 2 ... Mr. Yuen Kam, chairman of the board of directors ... "Shares") of  Excellent China Healthcare Investment Limited ("KKR SPV") ...
(Date:8/26/2015)... SPRINGS, Florida , August 26, 2015 /PRNewswire/ ... of the biggest factors fueling the optimism in ... approvals, M&A,s, collaborations and life sciences advancements.  Active ... developments are Pressure BioSciences, Inc. (OTCQB: PBIO), Sequenom, ... (NASDAQ: SRPT ), Raptor Pharmaceutical Corp. (NASDAQ: ...
Breaking Biology Technology:Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7
... Pittsburgh-based Foundation,Radiology Group (FRG), a full-service ... diagnostic images for hospitals,announced today that James ... the,position of Chief Medical Officer. The appointment ... nationwide network of radiology physician groups to,provide ...
... Ill., April 15 , What and When, ... (Carotid,intima-media tHICkness in Atherosclerosis using pioGlitazOne) published,today in ... (CIMT) with ACTOS(R) (pioglitazone HCl) was,associated with increased ... compared to glimepiride., The increased effect on ...
... Also Sign Manufacturing and Distribution Agreement, ... Ranbaxy,Pharmaceuticals Inc. (RPI), a wholly owned ... that it has reached several,agreements with AstraZeneca. ... The third agreement pertains to Omeprazole 40mg,tablets, ...
Cached Biology Technology:James W. Backstrom, M.D., Named Chief Medical Officer of Foundation Radiology Group 2James W. Backstrom, M.D., Named Chief Medical Officer of Foundation Radiology Group 3New Data Published in Circulation Showed an Increase in HDL Cholesterol Levels with ACTOS(R) (pioglitazone HCl) 2New Data Published in Circulation Showed an Increase in HDL Cholesterol Levels with ACTOS(R) (pioglitazone HCl) 3Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation 2Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation 3
(Date:8/6/2015)... and TELTOW, Germany , August ... Siggraph Conference, SensoMotoric Instruments (SMI) shows the ... , based on Epson,s Moverio BT-200 see-through ... platform. With this new solution, unprecedented quality and efficiency ... interaction with context-sensitive displays. For the first time, professionals ...
(Date:8/5/2015)... , August 5, 2015 According ... Access Management Market by Software, Services, Vertical (BFSI, Airport, IT ... Geography - Global Forecast to 2020", published by MarketsandMarkets, ... Market globally into various segments. The global PIAM Market ... to $546.2 Million by 2019, at a CAGR of ...
(Date:8/5/2015)... The biosensors market is proving highly attractive ... newer sectors, and development of devices resulting in higher ... seen the entry of multiple participants each year with ... (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) Recent ... Global Biosensors Market ( http://www.frost.com/nee9 ), finds that ...
Breaking Biology News(10 mins):SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4
... of Long Beach and Riverside are responsible for a significant ... air pollution and ship emissions on the disease has likely ... California (USC). The study, which appears in an ... , estimated that nine percent of all childhood asthma cases ...
... Oklahoma at Norman has received more than $10 ... part of the federal stimulus program, bringing thetotal ... to $23 million. Thirty-three projects achieved stimulus ... "The university has thoughtfully undertaken a systematic approach ...
... (Nasdaq: AWRE ), a leading supplier of broadband technology ... quarter ended September 30, 2009. , Michael ... we announced an agreement to sell our DSL and home ... being spun out of Infineon. This transaction represents the ...
Cached Biology News:USC study finds big air pollution impacts on local communities 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 3Aware, Inc. Reports Third Quarter 2009 Financial Results 2Aware, Inc. Reports Third Quarter 2009 Financial Results 3Aware, Inc. Reports Third Quarter 2009 Financial Results 4Aware, Inc. Reports Third Quarter 2009 Financial Results 5Aware, Inc. Reports Third Quarter 2009 Financial Results 6Aware, Inc. Reports Third Quarter 2009 Financial Results 7
PPIF Antibody...
Glutamate Receptor 5/1a...
... Rabbit monoclonal [EP282Y] to Asparagine ... all tested applications). ... corresponding to residues in the ... Entrez GeneID: ...
Shh Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Biology Products: